Literature DB >> 11413259

Patients with Alzheimer's disease and dementia with Lewy bodies mistaken for Creutzfeldt-Jakob disease.

H J Tschampa1, M Neumann, I Zerr, K Henkel, A Schröter, W J Schulz-Schaeffer, B J Steinhoff, H A Kretzschmar, S Poser.   

Abstract

OBJECTIVES: To describe the clinical presentation of patients with Alzheimer's disease (AD) or dementia with Lewy bodies (DLB) who were suspected of having Creutzfeldt-Jakob disease (CJD) and to investigate whether current clinical diagnostic criteria cover these atypical forms of AD and DLB.
METHODS: Brains from necropsy were examined for the diagnosis of CJD at the German reference centre for spongiform encephalopathies. Symptoms and signs in patients with suspected CJD in whom necropsy showed AD (n=19) or DLB (n=12) were analysed. Their data were compared with a group of patients with CJD (n=25) to determine overlapping and discriminating clinical features. All patients were classified according to clinical diagnostic criteria for CJD, AD, and DLB.
RESULTS: Demented patients were suspected of having CJD if disease was rapidly progressing and/or focal neurological signs appeared and/or an EEG showed sharp wave complexes. Myoclonus and limb rigidity were the most common neurological signs in all three dementias. DLB was not suspected in any patient, although patients with DLB showed parkinsonism (58%) and fluctuations (58%). Periodic sharp wave complexes (PSWCs) in EEG typical of CJD were found in five patients with AD and one patient with DLB. 14-3-3 Protein in CSF was detected in 20 patients with CJD, in two patients with AD, but not in any patient with DLB. Although most patients with DLB or AD met the clinical criteria for their respective diagnosis (74% and 90%), they also fulfilled criteria for CJD (42% and 58%).
CONCLUSIONS: In patients with rapidly progressive dementia and focal neurological signs, CJD should be the first line diagnosis. Facing the triad dementia, myoclonus, and rigidity, AD should be considered if the disease course is longer and DLB is the differential diagnosis if parkinsonism or fluctuations are present. Findings on EEG or CSF typical of CJD do not exclude AD or DLB.

Entities:  

Mesh:

Year:  2001        PMID: 11413259      PMCID: PMC1737446          DOI: 10.1136/jnnp.71.1.33

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  35 in total

1.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease.

Authors:  S S Mirra; A Heyman; D McKeel; S M Sumi; B J Crain; L M Brownlee; F S Vogel; J P Hughes; G van Belle; L Berg
Journal:  Neurology       Date:  1991-04       Impact factor: 9.910

2.  An evaluation of the predictive validity and inter-rater reliability of clinical diagnostic criteria for senile dementia of Lewy body type.

Authors:  I G McKeith; A F Fairbairn; R A Bothwell; P B Moore; I N Ferrier; P Thompson; R H Perry
Journal:  Neurology       Date:  1994-05       Impact factor: 9.910

3.  Antemortem diagnosis of diffuse Lewy body disease.

Authors:  H A Crystal; D W Dickson; J E Lizardi; P Davies; L I Wolfson
Journal:  Neurology       Date:  1990-10       Impact factor: 9.910

4.  A simple and effective method for inactivating virus infectivity in formalin-fixed tissue samples from patients with Creutzfeldt-Jakob disease.

Authors:  P Brown; A Wolff; D C Gajdusek
Journal:  Neurology       Date:  1990-06       Impact factor: 9.910

5.  Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias.

Authors:  O L Lopez; I Litvan; K E Catt; R Stowe; W Klunk; D I Kaufer; J T Becker; S T DeKosky
Journal:  Neurology       Date:  1999-10-12       Impact factor: 9.910

Review 6.  Diffuse Lewy body disease and progressive dementia.

Authors:  C R Burkhardt; C M Filley; B K Kleinschmidt-DeMasters; S de la Monte; M D Norenberg; S A Schneck
Journal:  Neurology       Date:  1988-10       Impact factor: 9.910

7.  Neuroleptic sensitivity in patients with senile dementia of Lewy body type.

Authors:  I McKeith; A Fairbairn; R Perry; P Thompson; E Perry
Journal:  BMJ       Date:  1992-09-19

8.  Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease.

Authors:  P Brown; C J Gibbs; P Rodgers-Johnson; D M Asher; M P Sulima; A Bacote; L G Goldfarb; D C Gajdusek
Journal:  Ann Neurol       Date:  1994-05       Impact factor: 10.422

Review 9.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

10.  Accuracy and reliability of periodic sharp wave complexes in Creutzfeldt-Jakob disease.

Authors:  B J Steinhoff; S Räcker; G Herrendorf; S Poser; S Grosche; I Zerr; H Kretzschmar; T Weber
Journal:  Arch Neurol       Date:  1996-02
View more
  32 in total

Review 1.  Long-term cholinesterase inhibitor treatment of Alzheimer's disease.

Authors:  Peter Johannsen
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

2.  Re: Creutzfeldt-Jacob disease misdiagnosed as dementia with Lewy bodies.

Authors:  A J Larner
Journal:  J Neurol       Date:  2006-03-06       Impact factor: 4.849

3.  Detailed electroencephalographic long-term follow-up study in Lewy body dementia with periodic sharp wave complexes.

Authors:  J L Fernández-Torre; J Figols; I Alonso; C Leno; M Martínez-Martínez; R Carpizo; M Altable
Journal:  J Neurol       Date:  2007-03-07       Impact factor: 4.849

4.  Pattern of cortical changes in sporadic Creutzfeldt-Jakob disease.

Authors:  H J Tschampa; K Kallenberg; H A Kretzschmar; B Meissner; M Knauth; H Urbach; I Zerr
Journal:  AJNR Am J Neuroradiol       Date:  2007 Jun-Jul       Impact factor: 3.825

Review 5.  Hashimoto's encephalopathy : epidemiology, pathogenesis and management.

Authors:  Ramon Mocellin; Mark Walterfang; Dennis Velakoulis
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 6.  Issues for clinical drug development in neurodegenerative diseases.

Authors:  Michel Dib
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Treatable neurological disorders misdiagnosed as Creutzfeldt-Jakob disease.

Authors:  Numthip Chitravas; Richard S Jung; Diane M Kofskey; Janis E Blevins; Pierluigi Gambetti; R John Leigh; Mark L Cohen
Journal:  Ann Neurol       Date:  2011-06-14       Impact factor: 10.422

8.  Serum tau protein as a marker for the diagnosis of Creutzfeldt-Jakob disease.

Authors:  Moeko Noguchi-Shinohara; Tsuyoshi Hamaguchi; Ichiro Nozaki; Kenji Sakai; Masahito Yamada
Journal:  J Neurol       Date:  2011-03-01       Impact factor: 4.849

Review 9.  Rapidly progressive dementia.

Authors:  Michael D Geschwind; Huidy Shu; Aissa Haman; James J Sejvar; Bruce L Miller
Journal:  Ann Neurol       Date:  2008-07       Impact factor: 10.422

10.  Rapidly progressive neurodegenerative dementias.

Authors:  Keith A Josephs; J Eric Ahlskog; Joseph E Parisi; Bradley F Boeve; Brian A Crum; Caterina Giannini; Ronald C Petersen
Journal:  Arch Neurol       Date:  2009-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.